Asthma MedDRA version: 17.0 Level: LLT Classification code 10049106 Term: Asthma chronic System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 17.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 17.0 Level: LLT Classification code 10003565 Term: Asthmatic System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 17.0
Conditions
Interventions
Trade Name: Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder.
Pharmaceutical Form: Inhalation powder
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Concentratio
Sponsors
Zambon Spa
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female patient = 18 years old. 2. Written informed consent obtained. 3. Patient with a documented diagnosis of asthma according to the Global Initiative for Asthma (GINA) guidelines 4. Patient with a co-operative attitude and ability to correctly use the DPI. 5. Female patient of childbearing potential who confirm that a reliable method of contraception was used at least 14 days before visit 1 and will continue to use a reliable method of contraception during the study, or post-menopausal women (at least 12 months of amenorrhea) 6. Patient must be stable and treated in accordance with the GINA guidelines. 7. Patient must be a non-smoker or ex-smoker who have stopped smoking at least 1 month prior to visit 1 and has a smoking history of =65 years) yes F.1.3.1 Number of subjects for this age range 10
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating female. 2. Unstable patient who developed an asthma exacerbation in the 4 weeks before screening. 3. Patient with upper or lower airways infection in the 4 weeks before screening. 4. Patient unable to perform pulmonary function testing. 5. Patients unable to withdraw fixed combination or long acting bronchodilator inhalation products 6. Patient with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study. 7. Patient with active lung cancer or any other chronic disease with poor prognosis and /or affecting patient status. 8. Patient with allergy, sensitivity or intolerance to study drugs and/ or study drug formulation ingredients. 9. Patient unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study. 10. Patient who received systemic corticosteroids within the last 4 weeks prior to visit 11. Patient who received any investigational new drug within the last 4 weeks prior to visit 1 and is participating in any clinical trial. 12. Patient with a history of alcohol or substance abuse that in the opinion of the investigator may be of clinical significance 13. Patient with diagnosis of Chronic Obstructive Pulmonary Disease (COPD). 14. Patients who has a lactose intolerance or history of allergy to milk proteins. 15. Patients treated with medications or herbal medicines that are strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, indinavir, nelfinavir, saquinavir, atazanavir, ketoconazole, itraconazole, voriconazole, fluconazole, cyclosporine, mibefradil, nefazodone, clarithromycin, telithromycin, troleandromycin, norfloxacin, ciprofloxacin) or inducers (e.g. phenobarbital, phenytoin, barbiturates, carbamazepine, oxcarbazepine, rifabutin, rifampin, St John’s wort) within 2 weeks prior to Screening Visit and during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of this study is to evaluate the effect of the products under investigation on Functional respiratory imaging parameters and evaluate the particle deposition with Computational fluid dynamics (CFD).;Secondary Objective: The secondary objectives of this study are to assess the effect of Z7200 and Symbicort® on lung function (spirometry and body plethysmography), on exercise capacity (6MWT)and on dyspnea (Borg CR10 Scale and VAS dyspnea). Furthermore the safety of the 2 products under investigation will be evaluated through monitoring of adverse events throughout the study;Primary end point(s): The parameters that will be obtained with Computational fluid dynamics (CFD) and used as primary outcome parameters are: - Total airway volume and total airway resistance - The number of deposited particles per pre-defined airway section;Timepoint(s) of evaluation of this end point: December 2014 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Secondary outcome variables that will be obtained with respective tests are listed below: Spirometry/ Lung function : - Forced Expiratory volume in 1 sec (FEV1), - Forced Vital Capacity (FVC), - Peak Expiratory Flow (PEF), - Maximum Expiratory Flow at 25% of FVC (MEF50), - Maximum Expiratory Flow at 50% of FVC (MEF25), - Inspiratory Vital Capacity (IVC), - Tiffeneau Index (FEV1/FVC ratio) Bodyplethysmography - Functional Residual Capacity (FRC), - Total Lung Capacity (TLC), - Airway resistance: Airway Resistance (Raw), Specific airway conductance (SGaw) 6 Minute Walk Test - Exercise capacity: distance walked in 6 minutes (m) Borg CR10 Scale: measure of the present dyspnea Visual Analog Scale: measure of the difference in dyspnea before and after treatment;Timepoint(s) of evaluation of this end point: December 2014 | — |
Countries
Belgium
Contacts
Public ContactJan De Backer
Fluidda nv
Outcome results
None listed